IRX Share Price Performance
AU$0.033
0.01 (32.00%)
Price AU$0.033
Share PriceAU$0.033
InhaleRx Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IRX Community Narratives
There are no narratives available yet.
Recent IRX News & Updates
InhaleRx Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0062
- Gross Margin
- 100.00%
- Net Profit Margin
- -159.03%
- Debt/Equity Ratio
- -38.3%
InhaleRx Limited Competitors
Snowflake Analysis
About IRX
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Australian Market Performance
- 7 Days: 1.2%
- 3 Months: 5.0%
- 1 Year: 9.1%
- Year to Date: 9.2%
Over the last 7 days, the market has risen 1.2%, driven by gains of 3.8% in the Materials sector. In the last year, the market has climbed 9.1%. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›